Related Experiment Video
Updated: Aug 1, 2026

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus
Insights
This consensus panel provides a cardiac risk stratification for managing sexual dysfunction in cardiovascular disease patients. Most patients are low-risk and can safely resume sexual activity, with specific guidelines for intermediate and high-risk groups.
Area of Science:
- Cardiology
- Sexual Medicine
- Clinical Practice Guidelines
Background:
- Sexual dysfunction is prevalent and impacts quality of life.
- Strong association exists between sexual dysfunction and cardiovascular disease (CVD).
- Sexual activity carries potential cardiac risks, necessitating careful management.
Framework:
- Developed a consensus-based classification system for cardiac risk stratification (low, intermediate, high).
- Defined criteria for each risk category based on CVD conditions and risk factors.
- Provided an algorithm to guide physicians in managing sexual dysfunction in CVD patients.
Implementation:
- Low-risk patients (e.g., controlled hypertension, stable angina, uncomplicated MI) can resume sexual activity or receive treatment.
- Intermediate-risk patients require further cardiologic evaluation before risk restratification.
- High-risk patients (e.g., unstable angina, severe heart failure, recent MI) need cardiac stabilization before resuming sexual activity or treatment.
Implications:
- Facilitates safe management of sexual dysfunction in diverse CVD populations.
- Empowers clinicians with a structured approach to patient care.
- Aims to improve patient well-being and quality of life by addressing sexual health concerns within cardiac care.
Abstract:
Sexual dysfunction is highly prevalent in both sexes and adversely affects patients' quality of life and well being. Given the frequent association between sexual dysfunction and cardiovascular disease, in addition to the potential cardiac risk of sexual activity itself, a consensus panel was convened to develop recommendations for clinical management of sexual dysfunction in patients with cardiovascular disease. Based upon a review of the research and presentations by invited experts, a classification system was developed for stratification of patients into high, low, and intermediate categories of cardiac risk. The large majority of patients are in the low-risk category, which includes patients with (1) controlled hypertension; (2) mild, stable angina; (3) successful coronary revascularization; (4) a history of uncomplicated myocardial infarction (MI); (5) mild valvular disease; and (6) no symptoms and <3 cardiovascular risk factors. These patients can be safely encouraged to initiate or resume sexual activity or to receive treatment for sexual dysfunction. An important exception is the use of sildenafil in patients taking nitrates in any form. Patients in the intermediate-risk category include those with (1) moderate angina; (2) a recent MI (<6 weeks); (3) left ventricular dysfunction and/or class II congestive heart failure; (4) nonsustained low-risk arrhythmias; and (5) >/=3 risk factors for coronary artery disease. These patients should receive further cardiologic evaluation before restratification into the low- or high-risk category. Finally, patients in the high-risk category include those with (1) unstable or refractory angina; (2) uncontrolled hypertension; (3) congestive heart failure (class III or IV); (4) very recent MI (<2 weeks); (5) high-risk arrhythmias; (6) obstructive cardiomyopathies; and (7) moderate-to-severe valvular disease. These patients should be stabilized by specific treatment for their cardiac condition before resuming sexual activity or being treated for sexual dysfunction. A simple algorithm is provided for guiding physicians in the management of sexual dysfunction in patients with varying degrees of cardiac risk.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Heart Failure V: Medical Management
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care

